GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alexion Pharmaceuticals Inc (NAS:ALXN) » Definitions » Tangible Book per Share

Alexion Pharmaceuticals (Alexion Pharmaceuticals) Tangible Book per Share : $19.32 (As of Mar. 2021)


View and export this data going back to 1996. Start your Free Trial

What is Alexion Pharmaceuticals Tangible Book per Share?

Tangible book value per share is calculated as the total tangible equity divided by Shares Outstanding (EOP). Total tangible equity is calculated as the Total Stockholders Equity minus Preferred Stock minus Intangible Assets. Alexion Pharmaceuticals's tangible book value per share for the quarter that ended in Mar. 2021 was $19.32.

Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Alexion Pharmaceuticals Tangible Book per Share Historical Data

The historical data trend for Alexion Pharmaceuticals's Tangible Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alexion Pharmaceuticals Tangible Book per Share Chart

Alexion Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Tangible Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.89 -0.44 2.18 13.06 16.17

Alexion Pharmaceuticals Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Tangible Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.25 15.32 13.32 16.17 19.32

Competitive Comparison of Alexion Pharmaceuticals's Tangible Book per Share

For the Biotechnology subindustry, Alexion Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alexion Pharmaceuticals's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alexion Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Alexion Pharmaceuticals's Price-to-Tangible-Book falls into.



Alexion Pharmaceuticals Tangible Book per Share Calculation

Alexion Pharmaceuticals's Tangible Book Value Per Share for the fiscal year that ended in Dec. 2020 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(11651.2-0-8102.5)/219.5
=16.17

Alexion Pharmaceuticals's Tangible Book Value Per Share for the quarter that ended in Mar. 2021 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(12416.8-0-8148.4)/220.9
=19.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total equity is a balance sheet item and equal to total assets less total liabilities of the company. Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Alexion Pharmaceuticals  (NAS:ALXN) Tangible Book per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Alexion Pharmaceuticals Tangible Book per Share Related Terms

Thank you for viewing the detailed overview of Alexion Pharmaceuticals's Tangible Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Alexion Pharmaceuticals (Alexion Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
121 Seaport Boulevard, Boston, MA, USA, 02210
Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS. Strensiq and Kanuma target ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need in hematology, nephrology, metabolic diseases, neurology, cardiology, and other areas.
Executives
Daniel Bazarko officer: SVP, Controller, CAO C/O ALEXION PHARMACEUTICALS, INC. 121 SEAPORT BOULEVARD BOSTON MA 02210
Tanisha Carino officer: EVP & CCAO C/O ALEXION PHARMACEUTICALS, INC., 121 SEAPORT BOULEVARD, BOSTON MA 02210
Anne-marie Law officer: EVP, Chief Experience Officer C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Brian Goff officer: EVP & Chief Commercial Officer C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
John J Orloff officer: EVP, Research & Development C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015
Indrani Lall Franchini officer: EVP, Chief Compliance Officer C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
John T Mollen director 176 SOUTH STREET HOPKINTON MA 01748
David R Brennan director C/O INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Baker Bros. Advisors (gp) Llc director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667, director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Andreas Rummelt director C/O ALEXION PHARMACEUTICALS, INC. 352 KNOTTER DRIVE CHESHIRE CT 06410
Francois Nader director 550 HILLS DRIVE, BEDMINSTER NJ 07921
Baker Brothers Life Sciences Lp director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Deborah Dunsire director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Judith A Reinsdorf director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974

Alexion Pharmaceuticals (Alexion Pharmaceuticals) Headlines

From GuruFocus

Alexion to Report First Quarter 2021 Results on Monday, May 3, 2021

By Business Wire Business Wire 04-20-2021